Literature DB >> 3308489

Endothelial cell lysis induced by lymphokine-activated human peripheral blood mononuclear cells.

A M Miltenburg1, M E Meijer-Paape, M R Daha, L C Paul.   

Abstract

In vitro exposure of human peripheral blood mononuclear cells (PBMC) to interleukin 2 results in the generation of lymphokine-activated killer (LAK) cells. Such LAK cells exhibit cytotoxicity against a spectrum of tumor target cell lines whereas they apparently do not affect normal tissues. In this report we show that PBMC that have been activated with T cell growth factor lyse trypsinized human umbilical cord venous endothelial cells as well as endothelial cell monolayers in a dose-dependent manner. Microscopic analysis showed that during the 4-h incubation period cell clumps containing detached endothelial cells and LAK cells were formed. When these clumps were evaluated with trypan blue the endothelial cells stained positive whereas LAK cells excluded the dye. No lysis occurred when fresh PBMC were added to target endothelial cells. The endothelial cell kill could not be blocked with an anti-LFA-1 antibody nor with intact OKT3 or F(ab')2 fragments of WT32. We conclude that lymphokine-activated PBMC exhibit cell-mediated endothelial cell detachment and lysis.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3308489     DOI: 10.1002/eji.1830170926

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  13 in total

1.  Activated, cytotoxic lymphocytes in systemic vasculitis.

Authors:  A D Blann; D G Scott
Journal:  Rheumatol Int       Date:  1991       Impact factor: 2.631

2.  The influence of synovial fibroblasts on the phagocytosis of Staphylococcus by polymorphonuclear cells.

Authors:  D van Riessen; M R Daha; T J Smeets; F C Breedveld
Journal:  Rheumatol Int       Date:  1992       Impact factor: 2.631

3.  Inhibition of lymphokine-activated killer cell generation by cultured tumor cell lines in vitro.

Authors:  P J Guillou; P C Sedman; C W Ramsden
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

Review 4.  Delivering safer immunotherapies for cancer.

Authors:  Lauren Milling; Yuan Zhang; Darrell J Irvine
Journal:  Adv Drug Deliv Rev       Date:  2017-05-22       Impact factor: 15.470

5.  Short-term lymphokine stimulation of human peripheral blood mononuclear cells generates cytolytic activity against endothelial cells: involvement of natural killer cells.

Authors:  A M Miltenburg; M E Meijer-Paape; M R Daha; L C Paul
Journal:  Immunology       Date:  1988-09       Impact factor: 7.397

6.  Lack of T cell oligoclonality in enzyme-digested synovial tissue and in synovial fluid in most patients with rheumatoid arthritis.

Authors:  J M Van Laar; A M Miltenburg; M J Verdonk; M R Daha; R R De Vries; P J Van den Elsen; F C Breedveld
Journal:  Clin Exp Immunol       Date:  1991-03       Impact factor: 4.330

7.  Chloroquine inhibits T cell proliferation by interfering with IL-2 production and responsiveness.

Authors:  R B Landewé; A M Miltenburg; M J Verdonk; C L Verweij; F C Breedveld; M R Daha; B A Dijkmans
Journal:  Clin Exp Immunol       Date:  1995-10       Impact factor: 4.330

8.  Interactions between interleukin-2-activated lymphocytes and vascular endothelium: binding to and migration across specialized and non-specialized endothelia.

Authors:  G Pankonin; B Reipert; A Ager
Journal:  Immunology       Date:  1992-09       Impact factor: 7.397

9.  Lymphokine-activated killer cytotoxicity against leukaemic blast cells.

Authors:  J A Tratkiewicz; J Szer; R L Boyd
Journal:  Clin Exp Immunol       Date:  1990-04       Impact factor: 4.330

10.  Lymphokine-activated killer cells lyse human renal cancer cell lines and cultured normal kidney cells.

Authors:  A M Miltenburg; M E Meijer-Paape; M R Daha; L C Paul
Journal:  Immunology       Date:  1988-04       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.